|
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, PTEN deletion had poor prognostic value in astrocytomas IDH-wildtype (p = 0.015), while in GBM IDH-wildtype was associated with better overall survival (p = 0.042) as well as MGMT promoter methylation (p = 0.009).
|
31623593 |
2019 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.
|
30500933 |
2019 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The proposed radiomics signature accurately predicted MGMT promoter methylation in patients with astrocytomas, and achieved survival stratification for TMZ chemotherapy, thus providing a preoperative basis for individualised treatment planning.
|
30039219 |
2019 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
|
28791452 |
2017 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of the present study is to clarify the significance of ATRX loss and its correlation with p53 overexpression, IDH1/2 mutations, 1p/19q-codeletion and MGMT hypermethylation in supertentorial astrocytoma, and to determine the prognostic value of these factors in Chinese patients.
|
26395639 |
2016 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SATB1 expression was also significantly lower in astrocytoma specimens with MGMT promoter methylation than in those without MGMT promoter methylation.
|
23317753 |
2013 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies strongly support that MGMT status is a predictive factor for response to temozolomide treatment in elderly patients with malignant astrocytic gliomas and its use for therapy decisions could improve patient management, avoid treatment toxicities and save costs.
|
23083460 |
2013 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This cut-off value distinguished diffuse astrocytomas with high and low MGMT expression.
|
22020830 |
2012 |
|
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relationship between chromosome 1p and 19q deletions and treatment responsive oligodendrogliomas is discussed, as are the newer advances relating to silencing of the MGMT gene in astrocytomas and mutations in the IDH-1 gene in both astrocytomas and oligodendrogliomas.
|
21233669 |
2011 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
It was found that MGMT promoter hypermethylation and TP53 mutations are both frequent and early events in the progression of astrocytomas and that their status is consistent over time.
|
20593220 |
2011 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Both oligodendrogliomas and astrocytic gliomas exhibited frequent methylation of MGMT.
|
22166632 |
2010 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
To address these questions, we determined MGMT activity promoter methylation and immunoreactivity in pretreatment and recurrent glioblastomas (GB, WHO Grade IV), and in astrocytomas (WHO Grade III).
|
20131314 |
2010 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A (3p21.3), NORE1A (1q32.1) and BLU (3p21.3) have been shown to be downregulated by methylation in cancer, and PTEN (10q23.3) and MGMT (10q26.1) are located in areas commonly deleted in astrocytomas.
|
18616639 |
2009 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
For this, 162 astrocytic tumors WHO II-IV (36 diffuse astrocytomas WHO II, 51 anaplastic astrocytomas, 75 primary glioblastomas) as well as 25 glioblastoma infiltration zones and 19 glioblastoma relapses were analyzed for immunohistochemical MGMT protein expression using tissue microarray technique.
|
17965865 |
2008 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The promoters of the RASSF1A (3p21.3), BLU (3p21.3) and MGMT (10q26) genes were analyzed by MCA-MSP and MCA-Meth in 13 astrocytoma samples, 6 high grade glioma cell lines and 4 neuroblastoma cell lines.
|
18298842 |
2008 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our findings suggest that p14(ARF) hypermethylation and MGMT hypermethylation constitute distinct molecular pathways of astrocytoma progression, which could differ in biological behavior and clinical outcome.
|
17493032 |
2007 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
MGMT promoter methylation was found in 17 (38%) of the 45 newly diagnosed malignant astrocytomas.
|
15455376 |
2005 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
There is evidence that G:C-->A:T transition mutations at CpG sites in the TP53 gene are significantly more frequent in low-grade astrocytomas with promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene than in those without methylation.
|
15822813 |
2005 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation was found in 17 (38%) of the 45 newly diagnosed malignant astrocytomas.
|
15455376 |
2005 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
TP53 mutations are significantly more frequent in low-grade astrocytomas with promoter methylation of the O(6)-methylguanine-DNA methyltransferase repair gene, suggesting that, in addition to deamination of 5-methylcytosine, exogenous or endogenous alkylation in the O(6) position of guanine may contribute to the formation of these mutations.
|
15685439 |
2005 |
|
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The present findings indicate that aberrant methylation of the MGMT promoter independently augurs for an unfavorable clinical course in patients with low-grade diffuse astrocytomas.
|
12744471 |
2003 |
|
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To examine the potential immunostaining pattern of MGMT expression and to evaluate the possible relationship between p53 and MGMT regulation, we assessed MGMT and p53 accumulation on 35 cases of diffusely infiltrating astrocytomas.
|
14570288 |
2003 |
|
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methylation of the promoter of the gene for O (6)-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, which confers resistance to chemotherapy with alkylating agents, was detected in 47% of oligodendrogliomas and 48% of low-grade diffuse astrocytomas.
|
11907807 |
2002 |
|
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, G:C --> A:T transition mutations at CpG sites were significantly more frequent in low-grade astrocytomas with MGMT methylation (15/26, 58%) than in those without (3/28, 11%, P = 0.0004).
|
11577014 |
2001 |